ArticleJournal of synchrotron radiation2025
The current status and future prospects of the Synchrotron Radiation Protein Crystallography Core Facility at NSRRC: a focus on the TPS 05A, TPS 07A and TLS 15A1 beamlines.
Article in Journal of synchrotron radiation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 50th anniversary of the Stanford SSRL synchrotron radiation and protein crystallography initiative.Journal of synchrotron radiation · 2026Article
- The Adaptable Binding Cleft of RmuAP1, a Pepsin-like Peptidase fromBiomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Synchrotron Radiation Protein Crystallography Core Facility (SPXF) at the National Synchrotron Radiation Research Center has been pivotal in advancing structural biology research in Taiwan. Since the 1990s, Taiwan has invested in the development of synchrotron light sources, including the Taiwan Light Source and the Taiwan Photon Source, which have profoundly enhanced protein structure analysis capability. Through the high-performance beamlines, SPXF has enabled significant scientific achievements, contributing to disease research and drug development. The facility's move towards automation and its integration of advanced techniques, such as in situ serial synchrotron crystallography, underscore its commitment to meeting the evolving needs of the research community. The SPXF continues to foster innovation and collaboration, providing world-class resources for both domestic and international users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.